Checked
Schizophrenia Clinical Trials
Studies with U.S. locations that are recruiting, about to recruit or enrolling by invitation
Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.
- Open studies
- 135
- With at least one U.S. site
- States with a site
- 38
- Most studies
- California
- 55 studies
Recently updated studies
50 of 135, recruiting studies first. Choose a state to see studies near you.
- The Effects of Auditory Stimulation During Sleep on Brain Networks in SchizophreniaRecruitingNCT06386588· Massachusetts General Hospital
1 U.S. site in 1 state
- A Study to Evaluate the Effect of KarXT on Urological SafetyRecruitingPhase 4NCT07221877· Bristol-Myers Squibb
16 U.S. sites in 8 states
- A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRecruitingPhase 3NCT07424404· Karuna Therapeutics, Inc., a Bristol Myers Squibb company
56 U.S. sites in 22 states
- A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaRecruitingPhase 2NCT07459647· MapLight Therapeutics
45 U.S. sites in 15 states
- iTBS to Enhance Social Cognition in People With PsychosisRecruitingNCT06118268· Northwell Health
1 U.S. site in 1 state
- A Study of Brenipatide in Adult Participants With SchizophreniaRecruitingPhase 2NCT07410507· Eli Lilly and Company
32 U.S. sites in 15 states
- A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)RecruitingPhase 3NCT07288567· Bristol-Myers Squibb
20 U.S. sites in 10 states
- Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental IllnessRecruitingNCT05491538· VA Office of Research and Development
1 U.S. site in 1 state
- Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1RecruitingNCT07853807· Washington University School of Medicine
5 U.S. sites in 5 states
- Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsRecruitingPhase 4NCT05648591· Vanda Pharmaceuticals
11 U.S. sites in 7 states
- Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy ControlsRecruitingNCT07680114· University of Wisconsin, Madison
1 U.S. site in 1 state
- Volatility in Paranoia (VIP) Trial: An RCT of Changes in Volatility With PsychotherapyRecruitingNCT06835556· Vanderbilt University Medical Center
1 U.S. site in 1 state
- Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)RecruitingNCT07101094· Bristol-Myers Squibb
20 U.S. sites in 12 states
- A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaRecruitingPhase 1NCT07615426· Janssen Research & Development, LLC
8 U.S. sites in 6 states
- Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaRecruitingPhase 3NCT07686263· Karuna Therapeutics, Inc., a Bristol Myers Squibb company
34 U.S. sites in 9 states
- Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderRecruitingPhase 3NCT06229210· Intra-Cellular Therapies, Inc.
59 U.S. sites in 19 states
- NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaRecruitingPhase 3NCT07105098· Neurocrine Biosciences
7 U.S. sites in 5 states
- NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaRecruitingPhase 3NCT07114874· Neurocrine Biosciences
50 U.S. sites in 16 states
- Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaRecruitingPhase 3NCT07227818· Neurocrine Biosciences
22 U.S. sites in 9 states
- Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruitingPhase 2NCT07680946· TG Therapeutics, Inc.
2 U.S. sites in 2 states
- State Representation in Early Psychosis 2RecruitingNCT07834203· University of Minnesota
2 U.S. sites in 1 state
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) InhibitorRecruitingPhase 4NCT07105111· Neurocrine Biosciences
19 U.S. sites in 9 states
- A Study of LTX-001 In Adult Participants With Acute Exacerbation of SchizophreniaRecruitingPhase 1NCT07734493· Leal Therapeutics, Inc
10 U.S. sites in 7 states
- Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)RecruitingNCT05276050· The University of Texas Health Science Center, Houston
1 U.S. site in 1 state
- A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With SchizophreniaRecruitingPhase 2NCT07145918· AbbVie
7 U.S. sites in 5 states
- Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant SchizophreniaRecruitingPhase 3NCT07184619· Newron Pharmaceuticals SPA
5 U.S. sites in 5 states
- 52-week Open Label Safety-Tolerability StudyRecruitingPhase 3NCT07369154· LB Pharmaceuticals Inc.
23 U.S. sites in 13 states
- Genetic Basis of the Risk and Consequences of Cannabis Exposure in HumansRecruitingPhase 1NCT06058702· Yale University
1 U.S. site in 1 state
- A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXTRecruitingPhase 1NCT07061288· Bristol-Myers Squibb
8 U.S. sites in 6 states
- Activities to Change Your Mood: A Test of the Acceptability and Initial Efficacy in Clinical Samples and Healthy ControlsRecruitingNCT06911723· University of Alabama at Birmingham
1 U.S. site in 1 state
- Cerebellar Modulation of Cognition in PsychosisRecruitingNCT06107764· Mclean Hospital
2 U.S. sites in 1 state
- Enhancing Veteran-Clinical Collaboration in VA PRRCsRecruitingNCT06898879· VA Office of Research and Development
3 U.S. sites in 2 states
- Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)RecruitingNCT07379827· Bristol-Myers Squibb
55 U.S. sites in 17 states
- REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)RecruitingNCT07006935· Case Western Reserve University
1 U.S. site in 1 state
- Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderRecruitingPhase 3NCT05303064· Alkermes, Inc.
26 U.S. sites in 19 states
- Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar DisorderRecruitingPhase 1NCT05025605· BioXcel Therapeutics Inc
5 U.S. sites in 4 states
- Enhancing Prefrontal Oscillations and Working Memory in Early-course SchizophreniaRecruitingNCT05102929· Fabio Ferrarelli
1 U.S. site in 1 state
- Inter-Brain Synchrony in SchizophreniaRecruitingNCT07177261· University of California, Los Angeles
1 U.S. site in 1 state
- Bilateral Prefrontal and Insular TMS for Depression in SchizophreniaRecruitingNCT07060066· The University of Texas Health Science Center, Houston
1 U.S. site in 1 state
- Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia EpisodeRecruitingNCT05890183· University of California, Los Angeles
1 U.S. site in 1 state
- Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation TreatmentRecruitingNCT02916810· The University of Texas Health Science Center, Houston
1 U.S. site in 1 state
- Biomarkers to Enhance Early Schizophrenia TreatmentRecruitingPhase 4NCT06969755· Northwell Health
4 U.S. sites in 4 states
- Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With SchizophreniaRecruitingPhase 2NCT07467993· Novartis Pharmaceuticals
7 U.S. sites in 6 states
- Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaRecruitingPhase 3NCT07363577· LB Pharmaceuticals Inc.
13 U.S. sites in 7 states
- Cognitive Strategies in Early Psychosis 2RecruitingPhase 3NCT07263022· University of Minnesota
1 U.S. site in 1 state
- Transition Care for FEPRecruitingNCT07713849· University of Chicago
2 U.S. sites in 1 state
- Tolerability of MDMA in SchizophreniaRecruitingPhase 1, Phase 2NCT05770375· Anya Bershad, MD, PhD
1 U.S. site in 1 state
- Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental IllnessRecruitingNCT04940663· Massachusetts General Hospital
1 U.S. site in 1 state
- Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental IllnessRecruitingPhase 2NCT06376734· Brigham and Women's Hospital
2 U.S. sites in 2 states
- MicroRNAs as Biomarkers in First Episode SchizophreniaRecruitingNCT07703670· Northwell Health
1 U.S. site in 1 state
Schizophrenia studies by state
Frequently asked questions
- How many schizophrenia clinical trials are recruiting?
- 135 schizophrenia studies on ClinicalTrials.gov have at least one U.S. site and are open or about to open, out of 27,256 open U.S. studies overall.
- Which states have the most schizophrenia trials?
- California (55), Texas (38), Georgia (32) have the most studies with a site in the state.
- What does recruiting mean?
- Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
- How do I join a clinical trial?
- Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.
Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/26/2026